Drugs / Ralfinamide
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00736151 | May 2004 → Apr 2007 | neuropathy, painful | Newron Pharmaceuticals SPA | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01019824 | Mar 2009 → May 2010 | — | Newron Pharmaceuticals SPA | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ralfinamide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01019824 ↗ |
| Known as | FCE-26742A | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107771 ↗ |
| Known as | NW1029 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107771 ↗ |
| Known as | PNU-0154339E | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107771 ↗ |
| Known as | Priralfinamida | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107771 ↗ |
| Known as | Priralfinamide | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107771 ↗ |
| Action | Inhibit | “Voltage-gated N-type calcium channel alpha-1B subunit blocker” CHEMBL2107771 ↗2“voltage-dependent, Na+-channel blockade” NCT01019824 ↗ “Monoamine oxidase B inhibitor” CHEMBL2107771 ↗ |
| Modality | Small molecule | — CHEMBL2107771 ↗ |
| Route | Oral | “Oral tablets administered at rising doses of 80 - 320 mg/day” NCT00736151 ↗ |
| Target | CACNA1B | “Voltage-gated N-type calcium channel alpha-1B subunit blocker” CHEMBL2107771 ↗ |
| Target | MAOB | “Monoamine oxidase B inhibitor” CHEMBL2107771 ↗ |